HOUSTON, April 5, 2013 /PRNewswire/ -- Novum Pharmaceutical Research Services, a leading contract research organization (CRO) serving the pharmaceutical industry in Phase I-Phase IV clinical trials and related services, announced today the opening of a new early-stage clinical facility in Houston, TX. The 55,000 square foot facility is scheduled to be operational in August, 2013.
"This exciting new facility reflects Novum's continued growth and our deep commitment to our clients' needs," said Christopher H. Chamberlain , Novum's Chief Executive Officer. "Like our other research facilities, it will provide a safe, convenient, and pleasant environment for our study participants," he added.
The GCP-compliant facility is being custom-built in Houston's Westchase district, a short distance from Novum's current clinics. The new facility will have seven research units that are designed to make the most efficient use of its 225 beds. Additionally, a 12-bed intensive monitoring unit will allow for early phase research studies requiring continuous cardiac and other specialized safety monitoring. The floor plan and layout will provide a high degree of flexibility in space planning to handle multiple types of study designs.
"While our employees and study participants truly make the difference at Novum, bringing this state-of-the-art facility online will raise the bar for Novum and the industry," said Dr. Darin Brimhall , Novum's Vice President of Clinic Operations.
About Novum PRS
Novum is a contract research organization ("CRO") that provides Phase I through IV clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. Founded in 1972, it operates Phase I research facilities with a total of 550 beds in three USA locations. Novum's expanding clinical trials management group currently focuses on performing Phase II through IV clinical endpoint studies requiring large patient numbers in ambulatory disease populations. Visit http://www.novumprs.com for more information.
|SOURCE Novum Pharmaceutical Research Services|
Copyright©2012 PR Newswire.
All rights reserved